Sanofi and Aqemia have reached a $140 million research collaboration agreement to use AI to accelerate the discovery of innovative drugs. The collaboration aims to identify small molecule drug candidates in the field of therapeutics. AQEMIA will utilize its unique platform combined with AI to identify therapeutic targets of interest to Sanofi. The collaboration will encompass the entire drug discovery process.

AstraZeneca has signed a $247 million collaboration agreement with Absci to jointly develop cancer drugs. The partnership aims to develop novel generative AI models to create new and improved antibody therapies. Absci utilizes generative AI to design optimal drug candidates. The CEO of Absci stated that this brings new treatment options for cancer patients. The deal includes an upfront payment, research funding, milestone payments, and royalties.